The Oncology Institute, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+41.6% +$42M
$142M
SG&A↑+12.8% +$3M
$28M
D&A↓-4.4% -$75K
$2M
Operating Income↑+41.9% +$6M
$-8M
EBITDA↓-4.4% -$75K
$2M
Interest Expense↑+64.0% +$748K
$2M
Interest Income
—
Other Income/Expense↓-18557.1% -$6M
$-7M
Pretax Income↓-2.4% -$391K
$-17M
Tax Provision
$0
Net Income↓-2.4% -$391K
$-17M
Operating Margin↑+8.0pts
-5.9%
Net Margin↑+4.0pts
-12.1%
Effective Tax Rate↑+0.0pts
0.0%
Deferred Tax Assets↓-15.6% -$1M
$8M
Deferred Tax Liabilities
$0
ETR (Continuing Operations)
0.2%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
Operating Lease Cost↓-15.2% -$356K
$2M
Revenue YoY Variation↑+24.7pts
41.6%
Income YoY Variation↑+41.3pts
41.9%
Revenue QoQ Variation↑+3.6pts
3.9%
Income QoQ Variation↑+12.8pts
28.2%